LMP1 enhances aerobic glycolysis in natural killer/T cell lymphoma

Area of Science:

• Oncology
• Virology
• Metabolic Research

Background:

• Natural Killer/T cell lymphoma (NKTCL) is aggressive with poor outcomes for relapsed/refractory cases.
• The role of Epstein-Barr virus (EBV) in NKTCL pathogenesis, particularly its molecular mechanisms, remains incompletely understood.

Purpose of the Study:

• To elucidate how EBV's LMP1 protein influences aerobic glycolysis and cellular functions in NKTCL.
• To investigate the correlation between LMP1 expression and clinical characteristics, treatment response, and prognosis in NKTCL patients.

Main Methods:

• Integrated analysis of metabolic sequencing, mRNA sequencing, and immunoprecipitation coupled to mass spectrometry.
• In vitro and in vivo experimental assays to assess LMP1 effects on NKTCL cell function and glucose metabolism.
• Clinical data analysis correlating LMP1 expression with patient outcomes and imaging findings (SUVmax).

Main Results:

• LMP1 significantly enhances NKTCL cell proliferation, inhibits apoptosis, and reduces sensitivity to gemcitabine.
• LMP1 upregulates aerobic glycolysis in NKTCL cells, evidenced by increased glucose uptake, lactate production, and extracellular acidification rate.
• Higher LMP1 expression correlates with adverse clinical features, poorer treatment response, worse prognosis, and increased SUVmax in NKTCL patients.

Conclusions:

• LMP1 promotes NKTCL progression and alters glucose metabolism by competitively binding TRAF3 and activating the noncanonical NF-κB pathway.
• Modulating the NF-κB pathway impacts NKTCL cell aerobic glycolysis and biological functions, suggesting therapeutic potential.
• This study provides novel insights into LMP1's role in NKTCL glucose metabolism, opening avenues for targeted therapies.